Diabetes Obesity and Metabolism· 2026Q1
Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP
- 0citations
- Q1SCImago
- 2026year
Short summary
Once-weekly semaglutide (7.2 mg or 2.4 mg) significantly reduced adipose tissue volume by 11.1 L and thigh muscle fat infiltration by 0.92% points compared to placebo over 72 weeks in adults with obesity, while preserving sit-to-stand repetitions.
AI-generated from the title and abstract; the full text is not read.
Key points
- Semaglutide treatment (pooled 7.2 mg and 2.4 mg) reduced adipose tissue volume by an estimated 11.1 L (p < 0.0001) versus placebo over 72 weeks.
- Thigh muscle fat infiltration decreased by 0.92% points with semaglutide versus placebo (p = 0.001).
- Estimated reductions in lean body tissue (-1.7 L) and thigh skeletal muscle volume (-1.1 L) were not statistically significant (p=0.16 and p=0.07, respectively).
- The number of sit-to-stand repetitions in 30 seconds was preserved in the semaglutide groups compared to placebo.
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m 2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks. This prespecified secondary analysis assessed changes in MRI body composition and physical function. Results Of 1407 participants, 55 with a valid baseline scan were included (semaglutide 7.2 mg, n = 43, 2.4 mg, n = 6 [pooled semaglutide group, n = 49]; placebo, n = 6). Estimated treatment differences (95% confidence intervals; p ‐values) for absolute changes in adipose/muscle compartment volumes for the pooled semaglutide versus placebo group, respectively, were: −11.1 L (−16.5 to −5.7; p < 0.0001) for adipose body tissue, −1.5 L (−2.9 to −0.1; p = 0.04) for visceral adipose tissue, −1.7 L (−4.0 to 0.7; p = 0.16) for lean body tissue, −1.1 L (−2.3 to 0.1; p = 0.07) for thigh skeletal muscle volume and −0.92%‐points (−1.41 to −0.42; p = 0.001) for thigh muscle fat infiltration. Similar results were seen for relative changes in adipose/muscle compartment volumes. A sensitivity analysis for the semaglutide 7.2 mg group versus placebo showed similar results. A mean of 13 sit‐to‐stand repetitions in 30 s at baseline, and 15 repetitions at Week 72, was observed in the pooled semaglutide and placebo groups. Conclusions Semaglutide plus lifestyle intervention was associated with reductions in adipose tissue volume, skeletal muscle volume and skeletal muscle fat infiltration, with a preserved number of sit‐to‐stand repetitions. Further research to assess the impact of weight loss on skeletal muscle composition and function should be explored in the future. Trial Registration: ClinicalTrials.gov identifier NCT05646706
The authors' abstract, as published at the source. Diabetes Obesity and Metabolism, 2026 · DOI ↗
The rest is in the Pofolia app
Takeaways and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine